Analysts Anticipate China Biologic Products (CBPO) Will Announce Earnings of $1.28 Per Share

Wall Street analysts expect that China Biologic Products (NASDAQ:CBPO) will report $1.28 earnings per share (EPS) for the current fiscal quarter, according to Zacks. Zero analysts have provided estimates for China Biologic Products’ earnings. China Biologic Products reported earnings of $1.32 per share in the same quarter last year, which would indicate a negative year over year growth rate of 3%. The firm is scheduled to issue its next earnings results on Wednesday, May 2nd.

On average, analysts expect that China Biologic Products will report full-year earnings of $5.22 per share for the current fiscal year, with EPS estimates ranging from $5.09 to $5.34. For the next fiscal year, analysts expect that the business will report earnings of $5.84 per share, with EPS estimates ranging from $5.79 to $5.88. Zacks’ EPS averages are an average based on a survey of analysts that follow China Biologic Products.

How to Become a New Pot Stock Millionaire

China Biologic Products (NASDAQ:CBPO) last issued its earnings results on Wednesday, February 28th. The biopharmaceutical company reported $0.90 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.89 by $0.01. The business had revenue of $90.10 million for the quarter, compared to the consensus estimate of $85.15 million. China Biologic Products had a net margin of 18.34% and a return on equity of 21.30%. The firm’s revenue for the quarter was up 16.1% on a year-over-year basis. During the same period in the previous year, the company earned $0.95 earnings per share.

A number of equities analysts recently weighed in on CBPO shares. BidaskClub upgraded shares of China Biologic Products from a “strong sell” rating to a “sell” rating in a report on Wednesday, December 20th. TheStreet downgraded shares of China Biologic Products from a “b-” rating to a “c+” rating in a report on Thursday, March 1st. Zacks Investment Research downgraded shares of China Biologic Products from a “hold” rating to a “sell” rating in a report on Monday, January 29th. Jefferies Group restated a “buy” rating and set a $97.00 target price on shares of China Biologic Products in a report on Thursday, March 15th. Finally, Deutsche Bank set a $105.00 target price on shares of China Biologic Products and gave the stock a “buy” rating in a report on Friday, March 2nd. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and two have assigned a buy rating to the company. The company has an average rating of “Hold” and a consensus target price of $101.00.

A number of institutional investors and hedge funds have recently modified their holdings of the stock. SG Americas Securities LLC bought a new position in China Biologic Products during the fourth quarter worth $117,000. Legal & General Group Plc boosted its position in China Biologic Products by 41.2% during the third quarter. Legal & General Group Plc now owns 2,966 shares of the biopharmaceutical company’s stock worth $274,000 after purchasing an additional 865 shares during the period. Cubist Systematic Strategies LLC boosted its position in China Biologic Products by 73.2% during the third quarter. Cubist Systematic Strategies LLC now owns 4,617 shares of the biopharmaceutical company’s stock worth $426,000 after purchasing an additional 1,952 shares during the period. Landscape Capital Management L.L.C. boosted its position in China Biologic Products by 27.7% during the fourth quarter. Landscape Capital Management L.L.C. now owns 7,254 shares of the biopharmaceutical company’s stock worth $571,000 after purchasing an additional 1,573 shares during the period. Finally, JPMorgan Chase & Co. bought a new position in China Biologic Products during the third quarter worth $795,000. Institutional investors and hedge funds own 56.27% of the company’s stock.

Shares of CBPO opened at $86.84 on Wednesday. The firm has a market cap of $2,813.97, a P/E ratio of 17.54, a PEG ratio of 1.29 and a beta of 1.46. China Biologic Products has a 1-year low of $71.85 and a 1-year high of $120.46.

WARNING: “Analysts Anticipate China Biologic Products (CBPO) Will Announce Earnings of $1.28 Per Share” was published by The Lincolnian Online and is the property of of The Lincolnian Online. If you are reading this piece on another site, it was stolen and republished in violation of United States & international trademark & copyright legislation. The correct version of this piece can be accessed at https://www.thelincolnianonline.com/2018/04/18/analysts-anticipate-china-biologic-products-cbpo-will-announce-earnings-of-1-28-per-share.html.

China Biologic Products Company Profile

China Biologic Products Holdings, Inc engages in the research, development, manufacture, and sale of human plasma-based biopharmaceutical products to hospitals and inoculation centers in the People's Republic of China. It offers human albumin for treating shock caused by blood loss trauma or burn; raised intracranial pressure caused by hydrocephalus or trauma; oedema or ascites caused by hepatocirrhosis and nephropathy; and neonatal hyperbilirubinemia, as well as for the prevention and treatment of low-density-lipoproteinemia.

Get a free copy of the Zacks research report on China Biologic Products (CBPO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for China Biologic Products Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for China Biologic Products and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply